Total Revenue
Viatris Total Revenue decreased by 5.0% to $3.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.1%, from $3.25B to $3.52B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows a downward trend with a -5.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.58B | $4.54B | $4.34B | $4.19B | $4.12B | $4.08B | $3.88B | $3.73B | $3.92B | $3.94B | $3.84B | $3.66B | $3.80B | $3.75B | $3.53B | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B |
| QoQ Change | — | -0.9% | -4.3% | -3.5% | -1.8% | -0.9% | -5.0% | -3.8% | +5.1% | +0.6% | -2.7% | -4.5% | +3.6% | -1.2% | -5.9% | -7.8% | +10.1% | +5.0% | -1.5% | -5.0% |
| YoY Change | — | — | — | — | -10.1% | -10.1% | -10.7% | -11.0% | -4.8% | -3.3% | -1.0% | -1.8% | -3.1% | -4.8% | -8.1% | -11.2% | -5.6% | +0.2% | +5.0% | +8.1% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Brands | $2.36B | $2.36B | $2.17B | $2.12B | $2.28B | $2.44B | — | $2.33B |
| Generics | $1.42B | $1.38B | $1.35B | $1.13B | $1.28B | $1.31B | — | $1.18B |
| Lipitor | $348.40M | $375.60M | $355.90M | $388.00M | $387.90M | $396.10M | $377.30M | $462.00M |
| Norvasc | $161.90M | $168.90M | $166.20M | $172.30M | $182.70M | $179.70M | $175.20M | $210.00M |
| Lyrica ® | $124.30M | $129.90M | $127.00M | $112.60M | $128.10M | $126.50M | $119.80M | $120.60M |
| EpiPen® Auto-Injectors | $115.50M | $123.20M | $73.10M | $96.70M | $136.80M | $157.20M | $79.00M | $101.10M |
| Creon ® | $78.20M | $84.60M | $90.40M | $82.40M | $91.40M | $93.10M | $98.90M | $97.40M |
| Viagra ® | $106.10M | $100.20M | $88.60M | $98.50M | $100.30M | $105.20M | $104.20M | $95.00M |
| Zoloft ® | $58.90M | $60.60M | $58.20M | $60.20M | $61.10M | $66.80M | $66.80M | $72.60M |
| Celebrex ® | $72.20M | $74.10M | $67.10M | $63.40M | $70.00M | $73.30M | $66.20M | $67.10M |
| Yupelri ® | $54.50M | $62.20M | $66.60M | $58.30M | $66.60M | $71.40M | $70.60M | $62.50M |
| Effexor ® | $62.70M | $66.30M | $64.50M | $59.30M | $63.10M | $67.20M | $68.10M | $62.00M |
| Xalabrands | $45.60M | $41.20M | $37.10M | $37.10M | $40.70M | $38.60M | $42.00M | $39.20M |
| Dymista ® | $55.00M | $43.50M | $41.30M | $42.80M | $48.40M | $33.80M | $38.60M | $37.30M |
| Xanax ® | $35.40M | $38.60M | $36.50M | $32.30M | $33.90M | $34.20M | $39.50M | $34.80M |
| Influvac ® | — | $121.30M | $52.70M | — | — | $125.40M | $63.60M | — |
| Total | $3.80B | $3.75B | $3.53B | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B |
Net sales is derived from annual filings.
Complex GX and Biosimilars, Influvac ® were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | $2.33B | $2.31B | $2.16B | $1.90B | — | — | — | $2.03B |
| Greater China | $539.40M | $562.20M | $522.30M | $555.50M | $588.90M | $615.20M | $572.90M | $680.10M |
| Emerging Markets Segment | $582.30M | $535.30M | $514.00M | $523.10M | $556.90M | $571.80M | $565.80M | $537.40M |
| Japan, Australia and New Zealand Segment | $349.80M | $345.50M | $336.30M | $277.10M | $306.70M | $307.30M | $306.60M | $273.50M |
| Total | $3.80B | $3.75B | $3.53B | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Viatris's total revenue?
- Viatris (VTRS) reported total revenue of $3.52B in Q1 2026.
- How has Viatris's total revenue changed year-over-year?
- Viatris's total revenue increased by 8.1% year-over-year, from $3.25B to $3.52B.
- What is the long-term trend for Viatris's total revenue?
- Over 4 years (2021 to 2025), Viatris's total revenue has grown at a -5.4% compound annual growth rate (CAGR), from $17.89B to $14.30B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.